Merlo, Daniel, Stankovich, Jim, Darby, David, Butzkueven, Helmut, Van der Walt, Anneke, Bai, Claire, Kalincik, Tomas, Zhu, Chao, Gresle, Melissa, Lechner-Scott, Jeannette, Kilpatrick, Trevor, Barnett, Michael, Taylor, Bruce. Wolters Kluwer Health; 2021. Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis.

Zhu, Chao, Zhou, Zhen, Roos, Izanne, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph. BMJ Group; 2022. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.

Spelman, Tim, Horakova, Dana, Csepany, Tunde, Boz, Cavit, Lechner-Scott, Jeannette, Granella, Franco, Grand'Maison, Francois, van der Walt, Anneke, Zhu, Chao, Butzkueven, Helmut, Ozakbas, Serkan, Alroughani, Raed, Onofrj, Marco, Kalincik, Tomas, Prat, Alexandre, Terzi, Murat, Grammond, Pierre, Patti, Francesco. Elsevier; 2023. Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.

Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens. American Medical Association (AMA); 2023. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.

Foong, Yi Chao, Merlo, Daniel, Darby, David, Dobay, Pamela, van Beek, Johan, Hyde, Robert, Simpson-Yap, Steve, Butzkueven, Helmut, van Der Walt, Anneke, Gresle, Melissa, Zhu, Chao, Buzzard, Katherine, Lechner-Scott, Jeannette, Barnett, Michael, Taylor, Bruce V., Kalincik, Tomas, Kilpatrick, Trevor. Wiley-Blackwell; 2025. Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis.

Foong, Yi Chao, Merlo, Daniel, Darby, David, Dobay, Pamela, van Beek, Johan, Hyde, Robert, Butzkueven, Helmut, van der Walt, Anneke, Gresle, Melissa, Zhu, Chao, Buzzard, Katherine, Lechner-Scott, Jeannette, Barnett, Michael, Taylor, Bruce, Kalincik, Tomas, Kilpatrick, Trevor. Wiley-Blackwell Publishing Ltd.; 2024. Patient-determined disease steps is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis.